董事会谨此宣布任命刘博士接替刘先生担任上市规则第3.05条规定的本公司授权代表， 自2025年12月12 日起生效。紧随上述变更后，授权代表为刘博士及本公司的公司秘书吴嘉雯女士(吴女士)。董事会进一 步宣布，田先生将获委任为授权代表以接替刘博士，自2025年12月29日起生效。连同吴女士，自2025年 12月29日起，本公司授权代表为田先生及吴女士。 刘诚博士(刘博士)获委任为董事会主席， 自2025年12月12日起生效。 此外，于2025年9月16日，董事会批准建议根据首次公开发售后激励计划向刘先生授出合共420.45万份 购股权，惟须待股东批准后方可作实(2025年9月授出)。 鉴于本公司已宣布延迟寄发有关2025年9月授出 的通函及股东特别大会通告，且刘先生的辞任已于股东特别大会举行前生效，经进一步考虑后，董事会 谨此进一步宣布，2025年9月授出将自2025年12月12日起取消。取消2025年9月授出已经刘先生同意。 董事会进一步宣布，刘敏先生(刘先生)，现任本公司执行董事、主席及行政总裁，因个人事业发展原因 已于2025年12月12日起辞任本公司执行董事、主席及行政总裁职务以及董事会提名委员会及业务 ...

刘敏，现任公司执行董事、主席及行政总裁，因个人事业发展原因已于2025年12月12日起辞任执行董 事、主席及行政总裁职务以及董事会提名委员会及业务发展及策略委员会成员。 格隆汇12月12日丨药明巨诺-B(02126.HK)发布公告，田丰将获委任为行政总裁及执行董事，自2025年12 月29日起生效。刘诚获委任为董事会主席，自2025年12月12日起生效。 2025年9月16日，董事会批准建议根据首次公开发售后激励计划向刘敏授出合共420.449万份购股权，惟 须待股东批准后方可作实("2025年9月授出")。监于公司已宣布延迟寄发有关2025年9月授出的通函及股 东特别大会通告，且刘敏的辞任已于股东特别大会举行前生效，经进一步考虑后，2025年9月授出将自 2025年12月12日起取消。取消2025年9月授出已经刘敏同意。 ...

JW (Cayman) Therapeutics Co. Ltd 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2126） 董事會設有四個董事會委員會。下表提供各董事會成員在該等委員會所擔任 成員的資料。 非執行董事 劉誠博士 （主席） 李怡平醫生 高星女士 Sungwon Song博士 獨立非執行董事 何建昌先生 Debra Yu 醫生 陳炳鈞先生 – 1 – 董事名單與其角色和職能 藥明巨諾（開曼）有限公司* 董事會（「董事會」）成員載列如下： | 董事 | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | 業務發展及 策略委員會 | | --- | --- | --- | --- | --- | --- | | 李怡平醫生 | | | | | | | 高星女士 | | M | | | M | | Sungwon Song博士 | | | M | | | | 劉誠博士 | | | | | | | 何建昌先生 | | C | | C | | | Debra Yu 醫生 | | | C | M | C | | 陳炳鈞先生 | | M | M | | | 附註： C： 有關 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2126） (1) 委任行政總裁及執行董事； (2) 委任董事會主席； JW (Cayman) Therapeutics Co. Ltd (3) 行政總裁、主席及執行董事辭任； (4) 取消授出購股權； (5) 變更董事會委員會組成 及 (6) 變更授權代表 委任行政總裁及執行董事 藥明巨諾（開曼）有限公司（「本公司」，連同附屬公司統稱為「本集團」）之董事 （「董事」）會（「董事會」）欣然宣佈，田豐先生（「田先生」）將獲委任為本公司行 政總裁及執行董事，自2025年12月29日起生效。 田先生的履歷詳情如下： 田先生，48歲，在生物製藥行業擁有超過二十年的經驗。田先生在商業化、 市場營銷、企業運營和戰略管理方面擁有全面的專業能力。在加入本集團之 前，於2023年5月至2025年12月，其在長春金賽藥業有限責任公司擔任腫瘤事 業部總 ...

Market Overview - The Hong Kong stock market experienced a volatile trading day on December 9, with the Hang Seng Index closing down 1.29% at 25,434.23 points, the Hang Seng Tech Index down 1.90% at 5,554.68 points, and the National Enterprises Index down 1.62% at 8,936.41 points [1] - Technology stocks generally declined, with notable drops in Bilibili, Xiaomi, and Baidu, each falling over 3%, while Kuaishou and Meituan dropped over 2% [1] - Gold and non-ferrous metal stocks faced pressure, with Zijin Mining down over 4% [1] - Real estate stocks weakened significantly, with Yaloo Group plunging over 18% [1] - The semiconductor sector saw substantial declines, with Huahong Semiconductor down over 5% and SMIC down over 4% [1] - New consumption concept stocks also fell, with Pop Mart down over 5% [1] - Pharmaceutical stocks performed well, with Genscript Biotech rising 18%, Hongteng Precision up 11%, and Zhaoyan New Drug up 5.9% [1] Company News - Dongfeng Group reported cumulative sales of 1.697 million vehicles in the first 11 months, a slight decrease of approximately 0.3% year-on-year, while new energy vehicle sales reached 489,203 units, marking a 39.1% increase [2] - New天绿色能源 achieved a cumulative power generation of 13.3689 million MWh in the first 11 months, an increase of 8.04% year-on-year, with November's generation at 1.662 million MWh, up 24.45% [2] - Longyuan Power completed a cumulative power generation of approximately 69.0964 million MWh in the first 11 months, reflecting a year-on-year growth of 0.41% [2] - Greenland Hong Kong reported contract sales of approximately 6.823 billion yuan in the first 11 months, a decline of 22.6% year-on-year [3] - Sunny Optical Technology completed a share swap merger with GoerTek, with its subsidiary Ningbo Aolai holding approximately 31.31% of the shares, becoming the second-largest shareholder [3] - Zoomlion Heavy Industry completed the acquisition of 81% of the shares in Zoomlion Heavy Industry Finance Leasing (Beijing) [4] - Cambridge Technology plans to increase its investment in CIG USA by $100 million [5] - WuXi AppTec announced research data for JWCAR201 IIT at the 67th American Society of Hematology Annual Meeting [6] - Four Seasons Pharmaceutical's innovative drug Anjiuwei® was successfully renewed for inclusion in the 2025 National Basic Medical Insurance Drug List, while its innovative drug Xuanyue Ning® was included for the first time [6] - Yuan Da Pharmaceutical's Class 1 innovative drug GPN01360 successfully reached clinical endpoints in a Phase II clinical study conducted in China [7] - Agile Group's hearing has been further postponed to March 9, 2026 [8] Institutional Insights - Bank of China International views the recent market adjustment as a normal phenomenon in a bull market, maintaining a positive outlook for the Hong Kong stock market, predicting the Hang Seng Index could reach 30,100 points by December 2026 [9] - Huaxia Fund believes that the previous irrational panic in the tech sector has eased, and with AI development paths becoming clearer, it is advisable to position for a recovery in the market [9] - Everbright Securities notes that the Hang Seng Index's current P/E ratio is above its five-year average, indicating a reasonable valuation range, while the tech index has room for growth [9] - Guosen Securities suggests that the recent market adjustment opens up space for future growth, with significant net inflows from southbound funds into the Hong Kong market [10]

Market Overview - The US stock market experienced a collective decline, leading to a weak market sentiment in Hong Kong, with the Hang Seng Index down 0.84% to 25,549.90 points, the Hang Seng Tech Index down 1.32% to 5,587.69 points, and the National Enterprises Index down 1.12% to 8,981.84 points [1] Company News - Dongfeng Group reported cumulative sales of 1.697 million vehicles in the first 11 months, a year-on-year decrease of approximately 0.3%. New energy vehicle sales reached 489,203 units, marking a year-on-year increase of about 39.1% [2] - New天绿色能源 achieved a cumulative power generation of 13.3689 million MWh in the first 11 months, an increase of 8.04% year-on-year, with November's generation at 1.662 million MWh, up 24.45% year-on-year [2] - Longyuan Power completed a cumulative power generation of approximately 69.0964 million MWh in the first 11 months, reflecting a year-on-year growth of 0.41% [3] - Greenland Hong Kong reported contract sales of approximately 6.823 billion yuan in the first 11 months, a year-on-year decline of 22.6% [4] - Sunyu Optical Technology completed a share swap merger with Goer Optical, with its subsidiary Ningbo Aolai holding approximately 31.31% of the shares, becoming the second-largest shareholder [4] - Zoomlion Heavy Industry completed the acquisition of 81% equity in Zoomlion Heavy Industry Finance Leasing (Beijing) [5] - Cambridge Technology plans to increase its investment in CIG USA by $100 million [6] - WuXi AppTec announced research data for JWCAR201 IIT at the 67th American Society of Hematology Annual Meeting [7] - Four Seasons Pharmaceutical's innovative drug Anjiuwei® successfully renewed its inclusion in the 2025 National Basic Medical Insurance Drug List, while its innovative drug XuanYueNing® was included for the first time [7] - Yuanda Pharmaceutical's Class 1 innovative drug GPN01360 successfully reached clinical endpoints in Phase II clinical trials in China [8] - Agile Group's hearing has been further postponed to March 9, 2026 [9] Institutional Insights - Haitong International suggests that after market consolidation, a rebound is expected, with technology stocks having room for recovery. The rebound's strength will depend on policy implementation and potential interest rate cuts by the Federal Reserve [10] - Everbright Securities notes that the Hang Seng Index's current P/E ratio is above its 5-year average, indicating overall valuation recovery, while the tech index has just returned to its 5-year average, suggesting room for further valuation catch-up [10] - Guosen Securities predicts that the short-term adjustment in Hong Kong stocks opens up space for market growth in 2026, with net inflows from southbound funds exceeding 110 billion yuan in November [10]

Core Viewpoint - WuXi AppTec's JWCAR201, an autologous CAR-T product targeting CD19/CD20, shows promising safety and efficacy in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) based on preliminary data from an ongoing IIT study presented at the 67th American Society of Hematology Annual Meeting [1][4]. Group 1: Study Overview - The IIT study is a single-arm, open-label, multi-center, dose-exploration trial conducted in China, evaluating JWCAR201 at three dose levels: 25×10^6, 50×10^6, and 100×10^6 CAR+ T cells [1]. - As of October 30, 2025, seven patients have been infused with JWCAR201, completing safety, efficacy, pharmacokinetics, and pharmacodynamics assessments across the three dose groups [1]. Group 2: Patient Characteristics - The median age of the seven patients is 56 years (range: 42 to 72 years), with 42.9% being male [2]. - The patient cohort exhibits high-risk characteristics: 85.7% have DLBCL-NOS, 57.1% are non-GCB subtype, 57.1% have an International Prognostic Index (IPI) score of ≥3, and 71.4% have double-expressor lymphoma (MYC/BCL2) [2]. - 42.9% of patients had received three or more lines of prior treatment, with 71.4% being primary refractory and 85.7% being resistant to their most recent treatment [2]. Group 3: Efficacy Results - Preliminary results indicate a best overall response rate (ORR) of 100% (7/7) and a complete response rate (CRR) of 85.7% (6/7) among the infused patients [2]. - All six patients who achieved a response maintained it up to Day 180 or longer, with median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) yet to be reached, suggesting significant efficacy [2]. Group 4: Safety Profile - Initial safety results show that 42.9% of patients experienced grade 1 cytokine release syndrome (CRS), and 14.3% experienced grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS), with no high-grade CRS or ICANS reported [3]. - All patients experienced treatment-related adverse events, primarily manageable hematologic toxicities, including neutropenia, thrombocytopenia, and anemia, which resolved to baseline or fully recovered [3]. - The safety profile indicates that JWCAR201 treatment for r/r DLBCL is manageable and controllable [3]. Group 5: Future Outlook - The study is ongoing, aiming to accumulate longer follow-up data [4]. - Based on the results, the company believes JWCAR201 demonstrates excellent efficacy and a favorable safety profile, showcasing significant potential for rapid advancement to the IND stage [4].

Core Insights - WuXi AppTec's JWCAR201, an autologous CAR-T product targeting CD19/CD20, shows promising initial results in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) [1][2] Group 1: Study Overview - The study is a single-arm, open-label, multi-center, dose-exploration IIT research conducted in China, evaluating JWCAR201's safety and preliminary efficacy [1] - The initial dose was set at 25×10^6 CAR+ T cells, with exploration at three dose levels: 25×10^6, 50×10^6, and 100×10^6 CAR+ T cells [1] Group 2: Patient Demographics - A total of 7 patients were infused, with a median age of 56 years (range: 42 to 72 years), and 42.9% were male [2] - The patient cohort exhibited high-risk characteristics, including 85.7% with DLBCL-NOS, 57.1% with non-GCB subtype, and 57.1% having an International Prognostic Index (IPI) score of ≥3 [2] Group 3: Efficacy Results - The overall response rate (ORR) reached 100% (7/7), with a complete response rate (CRR) of 85.7% (6/7) [2] - All patients except one maintained their response for at least 180 days, indicating significant efficacy [2] Group 4: Safety Profile - Among the 7 patients, 42.9% experienced grade 1 cytokine release syndrome (CRS), and 14.3% had grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) [3] - No high-grade CRS or ICANS were reported, and no dose-limiting toxicities (DLT) occurred, suggesting a manageable safety profile [3] Group 5: Future Prospects - The company believes JWCAR201 demonstrates excellent efficacy and good overall safety, with manageable adverse reactions, indicating strong potential for advancement to the IND stage [3]

Core Viewpoint - WuXi AppTec's JWCAR201, an autologous CAR-T product targeting CD19/CD20, shows promising preliminary efficacy and safety in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients, as presented at the 67th American Society of Hematology Annual Meeting [1][4]. Group 1: Study Overview - The study is a single-arm, open-label, multi-center, dose-exploration IIT research conducted in China, evaluating JWCAR201's safety and preliminary efficacy in DLBCL patients [1]. - The initial dose was set at 25×10^6 CAR+ T cells, with exploration at three dose levels: 25×10^6, 50×10^6, and 100×10^6 CAR+ T cells [1]. Group 2: Patient Demographics and Characteristics - A total of 7 patients were infused with JWCAR201, with a median age of 56 years (range: 42 to 72 years), and 42.9% were male [2]. - The patient cohort exhibited high-risk characteristics: 85.7% had DLBCL-NOS, 57.1% were non-GCB subtype, and 57.1% had an International Prognostic Index (IPI) score of ≥3 [2]. - 42.9% of patients had received ≥3 lines of prior treatment, and 85.7% were resistant to their most recent treatment [2]. Group 3: Efficacy Results - Preliminary results indicated a best overall response rate (ORR) of 100% (7/7) and a complete response rate (CRR) of 85.7% (6/7) among the infused patients [2]. - All responses were sustained for at least 180 days, with median duration of response (DOR), progression-free survival (PFS), and overall survival (OS) yet to be reached, indicating significant efficacy [2]. Group 4: Safety Profile - Safety results showed that 42.9% of patients experienced grade 1 cytokine release syndrome (CRS), and 14.3% experienced grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) [3]. - No high-grade CRS or ICANS occurred, and no dose-limiting toxicities (DLT) were reported [3]. - Treatment-related adverse events were manageable and included expected hematologic toxicities, which resolved to baseline or fully recovered [3]. Group 5: Future Outlook - The study is ongoing to gather longer follow-up data, and the company believes JWCAR201 demonstrates excellent efficacy and manageable safety, showing significant potential for rapid advancement to the IND stage [4].

自願公告 藥明巨諾（開曼）有限公司* （於開曼群島註冊成立的有限公司） （股份代號：2126） 研究及發展更新 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 JW (Cayman) Therapeutics Co. Ltd 在第67屆美國血液學會年會上公佈JWCAR201 IIT研究數據 JW (Cayman) Therapeutics Co. Ltd（藥明巨諾（開曼）有限公司*）（「本公司」或「藥明 巨諾」，連同其附屬公司統稱「本集團」），一家獨立的、專注於研發、生產及商 業化細胞免疫治療產品的創新型生物科技公司，宣佈在第67屆美國血液學會年 會上公佈JWCAR201的IIT研究數據。 關於JWCAR201 JWCAR201是藥明巨諾自主研發的靶向CD19/CD20的自體CAR-T產品。 JWCAR201 IIT研究數據摘要 本次更新的資料來自於一項在中國開展的單臂、開放、多中心、劑量探索IIT研 究，起始劑量設為25×106 CAR+ T細胞， ...